SCYNEXIS INC (SCYX)
US8112922005 - Common Stock
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10...
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
Reiterating cash runway of > 2 years...
3 Stocks Under $10 With the Potential for Massive Gains
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.
3 Dirt-Cheap Drug Developers With Blockbuster Potential
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025
Read here about the top under-$10 growth stocks primed for financial success through strategic partnerships and innovative product offerings.
3 Stocks Under $10 With Mammoth Growth Prospects
Learn more about the growth stocks under $10 with progressive fundamentals in the healthcare and technology sectors.
SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024
SCYX stock results show that SCYNEXIS beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SCYNEXIS (NASDAQ:SCYX) just reported results for the first quarter of 2024.SCYN...
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SCYNEXIS (NASDAQ:SCYX) just reported results for the fourth quarter of 2023.SCY...
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study...
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of...
SCYX DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
WHY: NEW YORK, NY - (NewMediaWire) - January 8, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (the “Class Period”), of the important January 8, 2024 lead plaintiff deadline.
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
/PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against...
SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
/PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYX DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...
SCYNEXIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SCYNEXIS, Inc. ("Scynexis" or the...
Scynexis stock falls as GSK amends deal for Brexafemme
Scynexis (SCYX) stock dropped 9% after its license agreement for antifungal drug Brexafemme was amended by GSK (GSK) due to a recent product recall. Read more here.